Interviews

Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.

Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for advanced practitioner-led care.

UChicago Medicine’s Obada Shamaa, MD, PhD, discusses why bronchiectasis is underrecognized and how to personalize airway clearance and antibiotic plans.

Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.

Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.

Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

Adam Colborn, JD, discusses 340B reform, PBM policy, site-neutral payment, and other federal health policy issues to watch in 2027.

Jennifer S. Graff, PharmD, said payers need clearer standards to assess the reliability and credibility of patient experience data.

Oyepeju Abioye-Akintola, MD, MSc, says unreadable consent forms are a fixable barrier to oncology trial enrollment.

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what matters most to AYA patients.

Managed care organizations should start AI adoption with simple tools that build governance for future growth, Leanna Baker, PharmD, MS, said.

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.

At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

Clinicians at CHEST 2026 say costs and outcomes are shaped well beyond the ICU, from surgical choices to discharge planning and end-of-life talks.

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Karin Johnson, MD, urges Congress to back permanent standard time, citing sleep, heart, and teen health risks of daylight saving time.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.

Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear vendor lanes for AI.

UW Medicine’s Bessie A. Young, MD, MPH, explains how high-risk APOL1 variants, ancestry, and environmental factors shape kidney disease risk.

Providence’s Katherine R. Tuttle, MD, FASN, explains why semaglutide is preferred in T2D and CKD and how guidelines sequence added therapies.

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

Jordan Feld, MD, MPH, explains how HBsAg testing, NUC therapy, and monitoring capacity will shape access to hepatitis B functional cure.